American Medical Systems' US prostate trial begins, Euro launch ahead:
This article was originally published in Clinica
Executive Summary
American Medical Systems (AMS) has begun a phase I/II US trial of it AMS ProstaJect ethanol injection system for treating benign prostate hyperplasia (see Clinica No 942, p 22). The Minneapolis, Minnesota company expects to enrol patients from 13 US centres across the US. The transurethral device uses ethanol to ablate the cells of an enlarged prostate gland. AMS will launch the device in Europe this month.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.